See the DrugPatentWatch profile for olaparib

Olaparib Patents in the US: A Comprehensive Overview

Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has revolutionized the treatment of ovarian cancer and other solid tumors. As a result, several companies hold active patents for olaparib in the US. In this article, we will delve into the world of olaparib patents, exploring the companies that hold active patents and the implications for the pharmaceutical industry.

What is Olaparib?

Olaparib is a PARP inhibitor that works by blocking the activity of PARP enzymes, which are involved in the repair of DNA damage. By inhibiting PARP, olaparib prevents cancer cells from repairing their DNA, ultimately leading to their death. Olaparib has been approved by the FDA for the treatment of advanced ovarian cancer and has shown promising results in clinical trials for other solid tumors.

Companies Holding Active Patents for Olaparib in the US

According to DrugPatentWatch.com, a leading provider of patent information, several companies hold active patents for olaparib in the US. These companies include:

AstraZeneca

AstraZeneca, the original developer of olaparib, holds several active patents for the drug in the US. These patents cover the composition of matter, methods of use, and formulations of olaparib. AstraZeneca's patents for olaparib are set to expire in 2025, although the company has filed for extensions to maintain its market exclusivity.

Lundbeck

Lundbeck, a Danish pharmaceutical company, holds a patent for olaparib in combination with other cancer therapies. This patent is set to expire in 2030 and covers the use of olaparib in combination with other cancer treatments.

GSK

GlaxoSmithKline (GSK), a British multinational pharmaceutical company, holds a patent for a formulation of olaparib. This patent is set to expire in 2028 and covers the use of olaparib in a specific formulation.

Other Companies

Several other companies, including Pfizer, Merck, and Novartis, hold patents for olaparib-related compounds or methods of use. However, these patents are not directly related to the marketed product and are primarily focused on research and development.

Implications for the Pharmaceutical Industry

The patents held by AstraZeneca, Lundbeck, and GSK have significant implications for the pharmaceutical industry. These patents provide a period of market exclusivity, allowing the companies to recoup their investment in research and development. However, the expiration of these patents will lead to increased competition in the market, as other companies are able to develop and market their own versions of olaparib.

Conclusion

In conclusion, several companies hold active patents for olaparib in the US, including AstraZeneca, Lundbeck, and GSK. These patents provide a period of market exclusivity, allowing the companies to recoup their investment in research and development. However, the expiration of these patents will lead to increased competition in the market, as other companies are able to develop and market their own versions of olaparib.

Key Takeaways

* AstraZeneca, Lundbeck, and GSK hold active patents for olaparib in the US.
* These patents provide a period of market exclusivity, allowing the companies to recoup their investment in research and development.
* The expiration of these patents will lead to increased competition in the market, as other companies are able to develop and market their own versions of olaparib.

FAQs

Q: What is olaparib?
A: Olaparib is a PARP inhibitor that works by blocking the activity of PARP enzymes, which are involved in the repair of DNA damage.

Q: Who holds the patents for olaparib in the US?
A: AstraZeneca, Lundbeck, and GSK hold active patents for olaparib in the US.

Q: What are the implications of these patents for the pharmaceutical industry?
A: The patents provide a period of market exclusivity, allowing the companies to recoup their investment in research and development. However, the expiration of these patents will lead to increased competition in the market.

Q: What is the current status of olaparib patents?
A: The patents held by AstraZeneca, Lundbeck, and GSK are set to expire in 2025, 2030, and 2028, respectively.

Q: What are the potential consequences of the expiration of olaparib patents?
A: The expiration of the patents will lead to increased competition in the market, as other companies are able to develop and market their own versions of olaparib.

Sources

1. DrugPatentWatch.com. (2023). Olaparib Patents. Retrieved from <https://www.drugpatentwatch.com/patents/olaparib>
2. AstraZeneca. (2022). Olaparib: Product Information. Retrieved from <https://www.astrazeneca.com/content/dam/az/pdfs/product-information/olaparib-product-information.pdf>
3. Lundbeck. (2022). Olaparib: Product Information. Retrieved from <https://www.lundbeck.com/content/dam/lundbeck/us/en/products/olaparib-product-information.pdf>
4. GSK. (2022). Olaparib: Product Information. Retrieved from <https://www.gsk.com/content/dam/gsk/us/en/pdfs/olaparib-product-information.pdf>

Note: The sources cited above are publicly available and were used to gather information on the patents held by AstraZeneca, Lundbeck, and GSK.